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Abstract The availability of over-the-counter (OTC) pro-
ton pump inhibitors (PPIs) for the short-term (2 weeks)
management of frequent heartburn (C2 days/week) has
increased markedly, yet evidence-based recommendations
have not been developed. A panel of nine international
experts in gastroesophageal reflux disease developed con-
sensus statements regarding the risks and benefits of OTC
PPIs using a modified Delphi process. Consensus (based on
C80% approval) was reached through multiple rounds of
remote voting and a final round of live voting. To identify
relevant data, the available literature was searched and
summarized. Grading of Recommendations, Assessment,
Development and Evaluation (GRADE) system terminol-
ogy was used to rate the quality of evidence and strength of
recommendations; consensus was based on C2/3
agreement. After 4 rounds of review, consensus was
achieved for 18 statements. Notably, the available data did
not directly reflect OTC use, but instead, prescription use;
therefore, extrapolations to the OTC setting were often
necessary. This limitation is regrettable, but it justifies
performing this exercise to provide evidence-based expert
opinion on a widely used class of drugs. The panel deter-
mined that using OTC PPIs according to label instructions
is unlikely to mask the symptoms of esophageal or gastric
cancer or adversely impact the natural history of related
precursor conditions. OTC PPIs are not expected to sub-
stantially affect micronutrient absorption or bone mineral
density or cause community-acquired pneumonia,
Clostridium difficile infection, or cardiovascular adverse
events. However, OTC PPI use may be associated with
slightly increased risks for infectious diarrhea, certain
idiosyncratic reactions, and cirrhosis-related spontaneous
bacterial peritonitis. The available evidence does not sug-
gest that OTC PPI use consistent with label instructions is
associated with substantial health risks. To minimize
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potential risks, healthcare professionals and consumers
must actively participate in decision making when
managing reflux-related symptoms in the self-care setting.
Key Points
Based on the available data, the consensus panel
determined that OTC PPIs are unlikely to mask the
symptoms of esophageal or gastric cancer if used as
directed.
OTC PPIs are not likely to affect micronutrient
absorption or bone mineral density or cause
community-acquired pneumonia, Clostridium
difficile infection, or cardiovascular adverse events.
However, using an OTC PPI may increase the risks
for infectious diarrhea, certain idiosyncratic
reactions, and cirrhosis-related spontaneous bacterial
peritonitis.
1 Introduction
Due to the high prevalence of acid reflux-related symptoms
in the general population, the increasing availability of
over-the-counter (OTC) proton pump inhibitors (PPIs), and
the limited direct data that are available in this area, evi-
dence-based treatment recommendations are needed to
discuss the potential risks and benefits of treating gas-
troesophageal reflux symptoms in the OTC setting [1]. A
recently published position paper describes the benefits and
potential harms of using PPIs; however, it does not
specifically discuss issues related to OTC PPI use. It
focuses instead on use of PPIs that is more consistent with
prescription indications [2]. The authors suggest that PPIs
are essential for treating acid-related conditions, but that, as
with any drug therapy, there are potential risks. These
potential risks should not, however, outweigh the estab-
lished benefits of PPIs when they are used as indicated,
which means they should only be used when appropriate
and for the shortest duration of time to achieve symptom
response [2]. Many of the safety concerns related to the use
of PPIs have been observed in studies conducted under
conditions that are consistent with prescription use, which
differs from OTC use in several key ways that are relevant
for assessing safety [3]. Prescription PPIs are generally
administered at higher doses, the durations of treatment are
longer, and users of prescription PPIs often differ from
OTC users in terms of their underlying conditions, which
are frequently more severe [4, 5]. In contrast, OTC PPIs are
used for shorter durations and generally represent the lower
end of the dose range. Omeprazole was the first PPI to be
approved for OTC use and is widely available in multiple
international markets [6]. Omeprazole 20 mg is available
OTC for treating frequent heartburn (defined as having
symptoms C2 days/week) and is administered as a single
daily dose for 2 weeks [5]. In contrast, omeprazole 20 mg
once daily is used for 4–8 weeks for treating gastroe-
sophageal reflux disease (GERD), and omeprazole 40 mg
is used for 4–8 weeks for treating gastric ulcers [4]. By
their nature, users of prescription PPIs are directly under a
physician’s care for their perceived acid-related disease,
while users of OTC PPIs are not necessarily under a
physician’s care. As a result of these issues, interpreting the
evidence to address concerns related to OTC PPI use
requires reviewing the literature to identify relevant data
and systematically extrapolating these findings to the OTC
setting from studies that likely only indirectly address these
issues. Therefore, specifically exploring these issues in the
context of OTC use necessitates using evidence available
from studies conducted with prescription PPIs, for which
the safety profiles have been widely discussed. To achieve
this end, an international group of experts was convened to
develop evidence-based recommendations and provide
accompanying literature reviews to inform global best
practices among healthcare providers for the safe and
appropriate use of OTC PPIs in the self-care setting.
2 Methods
A panel of nine international experts comprising eight
gastroenterologists and one general practitioner convened
to develop consensus, evidence-based recommendations
for using OTC PPIs utilizing a modified, evidence-based
Delphi process [7, 8]. The concept for this panel was
conceived by the co-chairs (DAJ/POK) and discussed with
the sponsor, who provided full latitude to select the inter-
national working group to represent the perspectives of
general practitioners and gastroenterologists. Selection of
the consensus panel was led by the panel co-chairs in
August 2015. The members were primarily selected based
on their expertise in the areas of gastroenterology and/or
treating acid-related conditions. Additionally, their regio-
nal location was considered in order to provide interna-
tional representation and to gain a global perspective on
these topics. Because OTC PPIs may be more frequently
recommended in a general practice versus a specialty care
setting, a primary care physician was also included in the
group. The panel co-chairs also developed a preliminary set
of statements based on clinically important topics and
assigned statement leads to review the available literature
related to each topic based on their level of expertise in
these areas.
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To identify relevant evidence for each statement, the
statement leads conducted literature reviews based upon their
preferred search methodologies. These literature reviews
included searches of the PubMed and Cochrane databases and
were conducted beginning in September 2015 in preparation
for a live meeting in November 2015. Searches were con-
ducted utilizing terms that were based on relevant keywords
for each statement (e.g. proton pump inhibitor\AND[eso-
phageal cancer; Limits: humans). No limits were set on pub-
lication date, and the focus was on English-language
publications. After literature searches were completed, the
results were reviewed to identify the appropriate sources to be
summarized. Because the topics that were analyzed were
often based on indirect evidence, the criteria for determining
the relevance of the available data differed for each statement.
Additional relevant publications were identified by reviewing
the bibliographies of the relevant articles. During the same
time period that the literature searches were being conducted,
consensus for each statement was reached through a series of
three remote rounds of anonymous voting and feedback fol-
lowed by a fourth round at the live meeting.
The level of agreement was rated using a 5-point scale:
agree strongly (A?), agree with reservation (A), undecided
(U), disagree (D), or disagree strongly (D?). Consensus
was defined a priori as C80% of panelists strongly agreeing
or agreeing with reservation (A? or A). The quality of the
evidence (high: wwww; moderate: www; low: ww; very
low: w) supporting each statement and strength of rec-
ommendation were categorized using GRADE (Grading of
Recommendations Assessment, Development and Evalua-
tion) terminology [9] and were developed by the statement
leads and voted on by the panel using a consensus defini-
tion of at least two-thirds agreeing (yes/no) with the rating.
A full summary of the voting through each round is pro-
vided in Figure 1 (Online Resource 1) and Table 1 (Online
Resource 2), and questions about the integrity of the pro-
cess and a description of withdrawn statements are pro-
vided in Online Resource 3.
3 Delphi Statements
1. When taken in accordance with label instructions, PPIs
have not been shown to mask the symptoms of early
esophageal cancer or meaningfully delay presentation.
Available OTC PPIs would not be expected to differ.
A1: 78%; A: 22%
Recommendation: Strong
Evidence: w
It is extremely difficult to prove that PPI treatment does
not mask the symptoms of early esophageal cancer and,
therefore, delay its diagnosis and management. Esophageal
adenocarcinoma (EAC) is the only form of esophageal
cancer that is considered to be GERD related, so the
potential effects of PPI therapy were considered only in the
context of EAC [10]. The most common presenting symp-
tom of EAC is dysphagia [11], and since this is a feature of
locally advanced disease, it is unlikely to be ‘‘masked’’ by
short-term PPI use. No identified studies directly examined
whether PPIs can mask the symptoms of early esophageal
cancer. Rather, they focused on whether PPI use is a risk
factor for cancer or has a chemopreventive role in Barrett’s
esophagus (BE) [12–16]. Although some reports demon-
strated a higher than expected subsequent incidence of
esophageal cancer, this was largely attributable to prevalent
disease [17, 18]. Importantly, studies that have attempted to
assess the risk of esophageal cancer with PPI use generally
did not reflect OTC doses or treatment durations. Instead,
they have focused on the long-term use of prescription—or
even higher—PPI doses [17]. Therefore, individuals adher-
ing to label instructions for OTC PPIs are extremely unlikely
to have a delay in the diagnosis of EAC. Descriptions of an
additional study conducted in this area and the role of BE in
EAC are included in Data Summaries (Online Resource 4).
2. When taken in accordance with label instructions, it is
unlikely that OTC PPIs produce achlorhydria.
A1: 89%; A: 11%
Recommendation: Strong
Evidence: wwww
Results from multiple comparative pH studies demon-
strate that short-term use of PPIs at OTC doses does not
suppress acid production enough to produce achlorhydria
[19–22]. Although PPI therapy has the potential to increase
Helicobacter pylori infection-related atrophic gastritis and
metaplasia, an effect on gastric cancer incidence in this con-
text has not been observed [23, 24]. Therefore, the short-term
use of OTC PPIs is very unlikely to cause achlorhydria or
gastric atrophy, even in the presence of H. pylori infection.
These potential issues may be of greater concern in regions
such asAsia andLatinAmerica,where acid-related symptoms
are more likely to be attributable toH. pylori infection, peptic
ulcers, or an underlying malignancy [25], which should be
considered when initiating any form of PPI therapy.
3. When taken in accordance with label instructions, PPIs
have not been shown to meaningfully delay the
presentation of early gastric cancer. Available OTC
PPIs would not be expected to differ.
A1: 78%; A: 22%
Recommendation: Strong
Evidence: ww
No randomized, controlled trials (RCTs) were identified
that directly addressed this topic, but observational studies
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analyzing the association between PPI use and gastric
cancer incidence have been conducted. The various case
reports that were identified describe patients and use pat-
terns that are inconsistent with OTC PPIs in terms of the
dose and duration of treatment [26–30]. In a population-
based cohort study, a 2-fold greater risk of gastric cancer
was observed in patients with C15 PPI prescriptions [31],
yet no increased risk was observed with prolonged PPI
exposure in a recent US Food and Drug Administration
(FDA)-mandated follow-up study conducted with panto-
prazole [32]. The identified studies did not focus specifi-
cally on early gastric cancer; furthermore, they were biased
by the populations that were assessed, as well as types of
analyses [12, 17, 18, 33, 34]. Most studies showed that any
potential effects of PPIs tend to disappear with time and
that the most likely explanation for the effects is con-
founding by indication rather than causality. Additionally,
H. pylori infection status was not routinely determined in
these studies. Importantly, early gastric cancer is likely to
be asymptomatic, and any presenting symptoms would
likely be inconsistent with acid reflux [35–37], so there is
no indication that early gastric cancer causes symptoms
that would prompt patients to seek PPI treatment. Addi-
tional details and results of studies conducted in this area
are provided in Data Summaries (Online Resource 4).
4. When taken in accordance with label instructions,
OTC PPIs may improve symptoms of peptic ulcer or
GERD but are extremely unlikely to adversely affect
the natural history of the conditions. Individuals with
persistent ([1 month) or recurrent symptoms after use
of an OTC PPI should consult a physician.
A1: 56%; A: 33%; D: 11%
Recommendation: Strong
Evidence: w
No RCTs have evaluated the use of OTC PPIs in the
treatment of peptic ulcer disease or severe GERD (i.e.
erosive esophagitis). However, it is likely that patients
with these conditions will not experience adequate
symptom response to self-treatment with an OTC PPI or
their symptoms will recur rapidly after a 2-week course of
therapy [38, 39]. Individuals with frequent heartburn who
receive treatment with an OTC PPI for 2 weeks are likely
to respond adequately and not experience early symptom
recurrences, but those who do should be referred to a
physician for further evaluation [40, 41]. Additionally,
frequent heartburn that is consistent with what is descri-
bed in OTC PPI labelling is not generally associated with
more serious conditions or significant endoscopy results
[42]. A description of additional details related to this
topic is provided in Data Summaries (Online Resource 4)
[43, 44].
5. Patients with upper gastrointestinal alarm features




Although esophageal and gastric cancers are a global
concern, the risk is greater in developing countries [45, 46].
Some Asian countries with particularly high gastric cancer
rates have implemented national screening programs [47].
Screening is not recommended in developed countries
where individuals with typical reflux symptoms or dys-
pepsia have an extremely low probability of underlying
malignancy [45, 47–51]. Screening may therefore not be
directly relevant to OTC PPIs, which are used for indi-
viduals experiencing reflux symptoms. However, because
there are concerns about the potential for use of OTC PPIs
to delay seeking treatment for a more serious underlying
condition, this statement was included to acknowledge the
issue. The relevant issue is whether patients with upper
gastrointestinal (GI) symptoms should be investigated or
whether it is reasonable to offer OTC PPI therapy, at least
in patients who are not experiencing alarm features. Those
with alarm features—presumably indicating more
advanced disease—may have poorer outcomes than those
without alarm features [52]. However, while the presence
of alarm features indicates a need for endoscopy, their
absence does not preclude the presence of esophageal or
gastric malignancy, particularly in high-risk populations
[53, 54]. A description of the issues associated with low
diagnostic yield and low sensitivity of alarm features is
provided in Data Summaries (Online Resource 4).
6. Baseline or routine monitoring of iron, calcium,
magnesium, and vitamin B12 levels in those taking




Data from nested case–control studies, case reports, and
controlled trials suggesting that acid-suppressive therapy
may reduce the absorption of iron, calcium, magnesium,
and vitamin B12 [55–58] have raised concerns about
micronutrient deficiencies in individuals taking PPIs.
However, data from controlled trials suggest long-term
prescription PPI use has little effect on the absorption of
these nutrients [3, 55, 59–61]. Therefore, intermittent OTC
PPI use would not be expected to have any deleterious
effect on absorption of micronutrients. The FDA specifi-
cally warns clinicians about the potential for long-term
prescription PPI use to lower serum magnesium levels, but
they report that OTC PPI use consistent with the directions
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in the labelling will have very little risk of causing hypo-
magnesemia [62]. As in other areas, patients with pre-ex-
isting conditions or those taking concomitant medications
that can lead to the malabsorption of these elements should
consult their healthcare provider. A summary of LOTUS
(Long-Term Usage of Esomeprazole vs. Surgery for
Treatment of Chronic GERD) and SOPRAN (Safety of
Omeprazole in Peptic Reflux Esophagitis: A Nordic Open
Study), studies that analyzed vitamin and mineral absorp-
tion with long-term acid-suppressive therapy, is provided
in Data Summaries (Online Resource 4).
7. Patients requiring repeated courses of OTC PPIs do not
need baseline bone density measurement or bone





Because gastric acid plays an essential role in the
intestinal absorption of dietary insoluble calcium salts,
there is biological plausibility that PPI-induced
hypochlorhydria may reduce fractional calcium absorp-
tion [56, 63–65]. Thus, PPIs may, theoretically, lead to
decreased bone mineral density (BMD) and an
increased fracture risk. However, these concerns related
to PPI use are controversial in terms of causality and
are often based on misinterpreted data resulting from a
stratification bias associated with exposure risks. The
totality of data from long-term studies conducted with
prescription doses of PPIs indicates that there is a
limited independent risk for BMD loss or fractures
[65–72]. Additionally, any potential risk is likely rela-
ted to higher doses and long-term treatment. Therefore,
the occurrence of these bone complications with inter-
mittent use of PPIs at OTC doses is expected to be
inconsequential, which is consistent with a statement
provided by the FDA on this topic [73]. A description
of some key observational studies that analyzed the role
of PPI use and BMD is included in Data Summaries
(Online Resource 4).
8. There are rare idiosyncratic drug reactions that may be
associated with PPIs.
A1: 78%; A: 22%
Recommendation: Strong
Evidence: ww
The level of evidence supporting the relationship
between PPIs use and two important idiosyncratic drug
reactions [i.e. acute interstitial nephritis (AIN) and suba-
cute cutaneous lupus erythematosus (SCLE)], which is
derived from case series and small nested case–control
studies, is low [74–77]. Nevertheless, as for any other
medication, clinicians should consider PPIs to be potential
contributors and immediately discontinue use in patients
who develop AIN or SCLE within weeks or months of
initiating treatment. Subsequent reintroduction might be
considered after the clinical course is carefully assessed. A
description of some key studies that analyzed these
idiosyncratic drug reactions and PPIs is provided in Data
Summaries (Online Resource 4).
9. Patients who have ascites secondary to cirrhosis should
be advised to consult a physician about the slightly
increased risk for spontaneous bacterial peritonitis.
Although this association has been reported for only
prescribed PPIs, the relative risk with OTC PPI use has
not been studied. A risk/benefit assessment for any PPI
use in these patients, with close monitoring, is
warranted.
A1: 56%; A: 44%
Recommendation: Strong
Evidence: w
In cirrhotic patients, spontaneous bacterial peritonitis
(SBP) occurs in 10%–30% of inpatients [78] and 3.5% of
asymptomatic outpatients [79]. SBP is associated with
substantial morbidity [80] and a 1-year mortality
exceeding 60% [81]. Although prescription PPIs have
been associated with an increased risk of SBP in cirrhotics
with ascites [82–85], the relationship with OTC PPIs has
not been specifically examined. It is unclear how PPIs
might cause SBP, but translocation of small intestinal
bacteria into the peritoneal cavity, facilitated by impaired
immunity and increased small intestinal permeability in
liver disease, may be exacerbated by bacterial overgrowth
secondary to reduced gastric acidity [80]. It is recom-
mended that patients with cirrhosis be evaluated by a
gastroenterologist or hepatologist before initiating therapy
with a PPI or histamine 2 receptor antagonist (H2RA) to
ensure such treatment is indicated. A more detailed
description of some key studies that assessed the risk for
SBP in PPI users is included in Data Summaries (Online
Resource 4).
10. It is very unlikely that OTC PPI therapy leads to an
increased risk of community-acquired pneumonia.
A1: 78%; A: 22%
Recommendation: Strong
Evidence: ww
In the USA, 4.2 million ambulatory care cases of com-
munity-acquired pneumonia (CAP) were reported in 2006,
with mortality rates of 3.8–8.5% for 2007–2008 [86]. The
mechanisms underlying the relationship between acid
suppression and respiratory infection have not been clearly
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established. However, it has been postulated that acid
suppression allows bacteria, viruses, fungi, and other
organisms to proliferate in the proximal GI tract, whence
they can reflux into the upper and then lower respiratory
tract [87]. Importantly, however, GERD itself is associated
with an increased risk of bronchitis and pneumonia [88].
The strongest association between PPI use and CAP is
reported with short-duration therapy, suggesting proto-
pathic bias consistent with GERD as a confounder rather
than with PPI therapy as the cause of CAP [86, 87, 89–93].
This interpretation is supported by the finding that PPI use
is not associated with an increased hospitalization for CAP
in nonsteroidal anti-inflammatory drug users who do not
have GERD [94]. Additional background information and
more detailed descriptions of key studies of the risk for
CAP in PPI users are provided in Data Summaries (Online
Resource 4) [95].
11. Use of OTC PPIs may increase risk of infectious
diarrhea.
A1: 67%; A: 33%
Recommendation: Strong
Evidence: www
Infectious traveler’s diarrhea is highly prevalent; attack
rates range from 30 to 70% in higher-risk regions, such as
the Middle East, Africa, Central and South America, and
much of Asia [96]. There is biological plausibility that PPIs
increase the risk of bacterial enteric infection by decreasing
the gastric acid barrier to ingested organisms and poten-
tially altering gut flora [97–102]. The impact of intermit-
tent, short-term PPI treatment consistent with OTC
labelling on the risk for bacterial enteric infections is
unclear. The decision to continue using PPIs while trav-
elling should be individualized based on the relative risks
and benefits. Additional background information and more
detailed descriptions of key studies that assessed the risk
for infectious diarrhea with PPI use are provided in Data
Summaries (Online Resource 4) [103–105].
12. The use of OTC PPIs is not strongly associated with
increased risk of Clostridium difficile infection. There
is insufficient evidence to determine an associated
causal risk of relapsing C. difficile infection.
A1: 33%; A: 67%
Recommendation: Strong
Evidence: www
In the USA, there are an estimated half-million cases of
C. difficile infection per year, leading to 29,000 deaths
within 30 days of diagnosis [106, 107]. Results of obser-
vational studies suggest that it is biologically plausible that
PPIs may potentially increase the risk of C. difficile
infection by decreasing the gastric acid barrier or nega-
tively impacting the gut microbiome, allowing for survival
and/or passage of vegetative forms of the bacteria
[97, 102, 108–113]. Notably, however, the spore form,
which is commonly the infective form of the organism, is
not susceptible to gastric acid [111]. After an extensive
review, the FDA concluded that PPI use could be associ-
ated with C. difficile infection, but the majority of reviewed
studies only reported odds ratios (ORs) of\3, which are
generally too low to establish causality [114]. Importantly,
inappropriate PPI use is widespread, particularly in hospi-
tals where higher doses are used [115, 116]. Given the risk
for inappropriate use of PPIs, acid-suppressive therapy
should be used cautiously in at-risk patients. It is unlikely
that use of OTC PPIs by outpatients substantially increases
the risk of C. difficile. In scenarios where there is a high
risk of C. difficile infection, the need for PPIs should be
reviewed, particularly in those with histories of C. difficile
infection and/or a need for broad spectrum antibiotics
[102]. Additional background information and more
detailed descriptions of key studies that assessed the risk of
C. difficile infection with PPI use are provided in Data
Summaries (Online Resource 4) [117].
13. Patients taking medication, the absorption, metabo-
lism, or effect of which may be affected significantly
by PPI therapy, should be advised to consult with a





PPIs may interact with other medications by decreasing
gastric acidity (leading to subsequent changes in solubility
and absorption), by modifying metabolism [most com-
monly through the cytochrome P450 (CYP) enzyme sys-
tem], or by inhibiting extragastric renal proton pumps
(leading to altered drug excretion) [118, 119].
The solubility of atazanavir decreases at high pH
in vitro, leading to an 87% reduction in exposure when
administered in a buffered solution [120, 121]. Pharma-
cokinetic studies conducted in healthy volunteers have
reported widely varying degrees of decreased exposure
(10–94%) of atazanavir with concurrent use of an H2RA or
PPI based on the timing of administration [121]. The
clinical relevance of this interaction is unclear because the
effect of acid suppression is mitigated if atazanavir is taken
approximately 16 hours after the PPI and because ataza-
navir treatment outcomes are affected by other factors, in
particular, adherence to antiviral therapy [122]. The
potential effect of increased pH on ledipasvir solubility
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may also be mitigated by using acid suppressive therapies
at different times of the day [123].
Citalopram and its S-enantiomer, escitalopram, are
selective serotonin reuptake inhibitors that are metabolized
primarily by CYP3A4 and CYP2C19, and at higher doses
citalopram and escitalopram are associated with QT
interval prolongation [124]. The FDA has recommended
that the maximum dose of citalopram should be 20 mg
daily in older adults [124]. Based on the analysis of a
therapeutic drug monitoring database reporting markedly
increased serum escitalopram concentrations in patients
taking omeprazole and esomeprazole, the authors proposed
a dose reduction of 50% for escitalopram if coprescribed
with omeprazole or esomeprazole [125].
Renal proton pump inhibition is thought to be the
mechanism whereby PPIs decrease methotrexate clearance;
however, the clinical significance of this interaction is
likely to be small [126]. PPI coadministration, therefore, is
very unlikely to have any adverse impacts on patients
taking low, immunomodulatory doses of methotrexate for
inflammatory bowel disease, rheumatoid arthritis, or
psoriasis.
Although the clinical relevance of these potential
interactions is unclear, for patients with serious concomi-
tant medical conditions requiring use of immunosuppres-
sive, antiviral (e.g. for human immunodeficiency virus or
hepatitis C virus infection), or selective serotonin reuptake
inhibitor treatment or chemotherapy, use of an OTC PPI
should first be discussed with a healthcare provider. A
description of a systematic review of PPI drug interaction
studies and some other potential interactions is provided in
Data Summaries (Online Resource 4) [127–138].
14. The pharmacodynamic interaction of clopidogrel
with omeprazole and esomeprazole has not been
shown to have clinically meaningful adverse cardio-
vascular effects. Individuals being treated with
clopidogrel may continue using OTC PPIs.
A1: 33%; A: 56%; U: 11%
Recommendation: Strong
Evidence: wwww
There is ample evidence showing that PPIs can be safely
used in conjunction with clopidogrel to reduce the risk of
GI bleeding in patients requiring anticoagulant therapy
[139–142]. However, a recent systematic review of
observational studies has suggested a potential negative
effect on cardiovascular outcomes (ORs B1.4) in patients
treated with a PPI and clopidogrel, which is unlikely to be
clinically relevant [143]. Conversely, controlled trials
conducted with PPIs and clopidogrel have not demon-
strated any effects on cardiovascular outcomes [139, 144].
Although more rigorous data are needed to more clearly
quantify the potential risks of using PPIs with clopidogrel,
clinical experience suggests that the risk of negative car-
diovascular effects is low. A description of background
information and key studies that assessed the interaction
between clopidogrel and PPIs is provided in Data Sum-
maries (Online Resource 4) [145–148].
15. It is extremely unlikely that PPIs increase risk for
myocardial infarction. OTC PPIs would not be
expected to differ.
A1: 89%; A: 11%
Recommendation: Strong
Evidence: w
One postulated mechanism by which PPIs might cause
adverse cardiovascular events involves increasing asym-
metric dimethyl arginine (ADMA), a known risk factor for
cardiovascular events, which leads to decreased nitric
oxide synthesis and endothelium-dependent vasodilation
[149]. PPIs are thought to increase ADMA by binding to
and inhibiting dimethylarginine dimethylaminohydrolase,
which is responsible for metabolizing ADMA [150].
However, the available data suggest that the potential for
PPIs to cause myocardial infarction is low, and that any
observed association is likely attributable to other risk
factors [151–153]. A detailed description of the studies that
assessed the risk for adverse cardiovascular outcomes with
PPI use is provided in Data Summaries (Online Resource
4).
16. There is no contraindication for the use of category B
OTC PPIs for heartburn during pregnancy.
A1: 56%; A: 44%
Recommendation: Strong
Evidence: www
Gastroesophageal reflux symptoms commonly occur
during pregnancy [154, 155]. The FDA classifies omepra-
zole as category C based on potential embryotoxic and
fetotoxic effects in animal studies and similar concerns
from human case reports; all other PPIs are category B (no
fetal teratogenicity or harm; limited human pregnancy
data) [156, 157]. The American College of Gastroenterol-
ogy treatment guidelines recommend using PPIs when
clinically indicated during pregnancy [51], although a step-
up treatment approach should be utilized, beginning with
lifestyle changes, antacids/alginates, H2RAs, then culmi-
nating with PPIs [156, 158]. During pregnancy, an obste-
trician should always be consulted before any form of
pharmacotherapy is initiated. A more detailed description
of key studies conducted in pregnant women receiving PPI
therapy is provided in Data Summaries (Online Resource
4) [159–161].
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17. There is a rapid treatment response for heartburn with
OTC PPIs, which begins on day 1 for many patients.
A1: 78%; A: 22%
Recommendation: Strong
Evidence: wwww
Although PPIs often require multiple doses to produce
their full therapeutic effects [162, 163], a significant pro-
portion of individuals will experience significant changes
in gastric pH and associated reductions in symptom fre-
quency and severity beginning on the first day of treatment
with an OTC PPI [164–170]. Some patients report symp-
tom relief on the first day of PPI therapy, but the proportion
of patients who respond increases steadily during the
14-day treatment period. By day 14, the percentages of
heartburn-free days among those treated with omeprazole
20 mg, lansoprazole 15 mg, and esomeprazole 20 mg were
45–70% [166, 167, 169, 171]. There are data demonstrating
that certain PPIs have more rapid effects on intragastric pH
[172]. However, whether these differences produce a
clinically relevant effect on symptom response has not
been established. A more detailed description of the results
of these studies is provided in Data Summaries (Online
Resource 4).
18. As there is a rapid treatment response for heartburn-
related sleep impairment with PPIs, which begins on
day 1 in many patients, OTC PPIs are likely to have
the same effect.
A1: 67%; A: 33%
Recommendation: Strong
Evidence: www
Nocturnal reflux symptoms and related sleep impair-
ments are common and can have a significant negative
effect on quality of life, general well-being, and function-
ality [173–175]. PPIs, including pantoprazole 20 mg, lan-
soprazole 15 and 30 mg, and rabeprazole 10 and 20 mg,
have been shown to have a significant impact on nighttime
heartburn beginning on the first day of treatment
[168–170]. In two studies conducted with individuals not
specifically experiencing nocturnal heartburn, 43–46% of
those treated with esomeprazole 20 mg were heartburn free
on the first night of treatment [171]. A more detailed
description of these study results is provided in Data
Summaries (Online Resource 4) [176, 177].
4 Discussion
Many of the recommendations of this consensus panel are
based on indirect evidence, as potentially relevant studies
were not generally conducted in the OTC setting. In the
absence of direct evidence, results from studies in other
clinical scenarios were reviewed and extrapolated to OTC
use. The studies that were reviewed differed from the
OTC setting in terms of using higher doses, longer
durations of therapy, and enrollment of more severely ill
patients, yet any effect would not be expected to differ
meaningfully from what would be observed with OTC
PPIs. Notably, where there was an established or expected
relationship between the outcome and cumulative drug
exposure, the effect may be even less pronounced with
OTC PPIs. In such cases, consideration was made for the
applicability to the OTC setting. If there was an absence
of risk in this scenario, an assumption was made that
lower doses taken for shorter durations in a generally
healthier population would pose no greater risk than
prescription PPIs. From a practical standpoint, the process
of extrapolating findings from these studies may have
been further complicated by the lack of consistency in
labelling for different products in different regions. For
example, in the USA, the labelling for OTC PPIs indi-
cates that they should be taken for 14 days and that a
physician should be consulted if more than one course of
treatment every four months is necessary [163]. In the
EU, the duration of treatment for nonprescription PPIs is
up to 2 weeks, but the labelling specifically states that
when complete symptom relief is experienced, treatment
should be discontinued [178]. In addition, there is no
limitation on the number of treatment courses that can be
taken annually. Because these differences are relatively
minor, the material impact of these variations is not
known. For many statements, a qualifier was used (i.e.
‘‘when taken in accordance with label instructions’’) to
account for variations in approved indications and usage
instructions. Although these limitations are regrettable,
they reflect the data that are available in the scientific
literature, and in our opinion this lack of data provides
additional support for our decision to convene this con-
sensus panel. The Delphi process is utilized for areas of
research where the data are limited and incomplete to
allow for experts in the area to provide their opinion of
available data. This is particularly pertinent for a class of
drugs that is becoming more widely available without the
need to consult a physician.
A potential issue associated with use of OTC PPIs
involves allowing consumers direct access to these prod-
ucts without the need to consult a physician, which could
lead to inappropriate use by some individuals. Although
this is a potential concern, real-world-use data suggest that
individuals using OTC PPIs self-select appropriately based
on symptom presentation and are more likely to take the
appropriate number of doses or fewer rather than take more
than is recommended [179]. In addition, these data show
that those who required more than the recommended doses
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frequently consulted a physician. Other studies also suggest
that individuals with frequent symptoms of gastroe-
sophageal reflux will consult a physician when their
symptoms become more severe or frequent, significantly
impact their daily lives, or if alarm features appear
[180, 181].
Consistent with the tenets of evidence-based medi-
cine, results of RCTs were considered paramount.
However, definitive data from these studies were not
widely available and may never be conducted in many
instances, particularly in relation to safety. As such,
available epidemiological data from large administrative
databases and observational studies were interpreted
cautiously, due to the inherent limitation in their ability
to inform clinical practice as they are not designed to
determine causality, are subject to biases from potential
confounding variables, and often evaluate multiple end-
points [182]. As a result, the risk for observing spurious
effects is increased. It has, therefore, been suggested that
outcomes with ORs \3–4 may be the result of these
extrinsic factors rather than the treatment or other vari-
able that is being evaluated [182, 183]. Thus, findings
from observational studies that do not reach this
threshold—even if statistically significant—may not
have any actual clinical significance, particularly if the
underlying mechanisms have not been established.
Notably, subsequent to conducting the literature reviews
used for this consensus panel, additional studies have
been published that reported an increased risk for
chronic kidney disease [184] and dementia [185] asso-
ciated with PPI use. However, as is noted above and by
the authors of these reports, there are significant limi-
tations with these studies that preclude establishing a
causal relationship between these events and PPI use. As
a result, we did not feel the need to reconvene this panel
to address these reports.
5 Conclusions
Consensus statements and accompanying evidence-based
reviews were developed to provide guidance on the safe
and appropriate use of OTC PPIs for treating frequent
heartburn. Although direct evidence for many areas was
limited, based on the available empirical evidence and
clinical experience accumulated over nearly 30 years with
prescription and OTC PPIs, the panel considers that OTC
PPIs are generally safe and effective when used according
to the label instructions. To minimize the risk of adverse
outcomes associated with OTC PPIs, healthcare profes-
sionals should provide guidance to individuals taking them
to help them make appropriate treatment decisions and to
help identify specific risk factors.
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